Commonly used medications and endometrial cancer survival: a population-based cohort study.

Genomic Identification of Significant Targets (GISTIC) outputs for Circular Binary Segmentation (CBS) - or Piecewise Constant Fit (PCF) - segmented input data. The number of peaks attained by GISTIC on the y-axis is plotted against the two changing parameters α for CBS and γ for PCF on the x-axis. GISTIC peaks of amplification applying CBS-segmented data are illustrated in pink and PCF-segmented data in red, respectively. Deletion peaks are colored in green for CBS-segmented input data and in blue for PCF-segmented data. From top to bottom are shown GISTIC focal peaks for breast, ovarian, endometrial, and cervical cancers, to the left for PCF-segmented input data (A, C, E, and G) and to the right for CBS-segmented input data (B, D, F and H), respectively. For further analysis are the selected α and γ highlighted with a colored square. (PDF 362 kb

レーザー共鳴イオン化質量分析法を用いた極微量同位体分析に基づく原子力計測技術の高度化に関する研究

名古屋大学Nagoya University博士(工学)名古屋大学博士学位論文 学位の種類:博士(工学) (論文) 学位授与年月日:平成15年2月28日doctoral thesi

Site Selective Growth of GaAs-NWs on Patterned Si Substrate

Catalyst-free GaAs-nanowire (GaAs-NWs) have been studied . But, It doesn't achieve to growth GaAs-NWs on Si(001) substrate looking toward the opto-electronic integrated circuit (OEIC) and Micro Electro Mechanical systems (MEMS). So we attempted to make site selective growth of GaAs-NWs by using patterned Si substrate and investigated the flux condition of maximum GaAs-NWs density. We found that it is possible to selective growth of GaAs-NWs by patterned Si substrate and GaAs-NWs or GaAs layer morphology depend on Ga flux. For detail, Ga flux and As flux are less than 0.25 [ML/s] and 1.0 [ML/s] for maximum GaAs-NWs density. Additionally, we concluded relation between Ga flux and Ga droplet have an effect on relation between Ga flux and GaAs-NWs density.departmental bulletin pape

中国大陸産ササラダニ類目録 : 第1報

application/pdfdepartmental bulletin pape

Additional file 1: of GFRA3 promoter methylation may be associated with decreased postoperative survival in gastric cancer

β values for selected CpG-sites. (TXT 7 kb

Additional file 11: Table S6. of A systematic comparison of copy number alterations in four types of female cancer

GISTIC focal peaks for joint regions of CBS and PCF gains and losses. This table shows the GISTIC focal peaks of the overlapping regions between CBS and PCF. (XLSX 15 kb

Additional file 2: of A systematic comparison of copy number alterations in four types of female cancer

Supplementary methods (DOCX 398 kb

Additional file 1: Figure S1. of Gene expression analysis supports tumor threshold over 2.0Â cm for T-category breast cancer

Simulated array data. Top: simdat1, middle: simdat2, and bottom: simdat3. (PDF 86.2 kb

Differential Inhibition of <i>Ex-Vivo</i> Tumor Kinase Activity by Vemurafenib in <i>BRAF</i>(V600E) and <i>BRAF</i> Wild-Type Metastatic Malignant Melanoma

<div><p>Background</p><p>Treatment of metastatic malignant melanoma patients harboring <i>BRAF</i>(V600E) has improved drastically after the discovery of the <i>BRAF</i> inhibitor, vemurafenib. However, drug resistance is a recurring problem, and prognoses are still very bad for patients harboring <i>BRAF</i> wild-type. Better markers for targeted therapy are therefore urgently needed.</p><p>Methodology</p><p>In this study, we assessed the individual kinase activity profiles in 26 tumor samples obtained from patients with metastatic malignant melanoma using peptide arrays with 144 kinase substrates. In addition, we studied the overall <i>ex-vivo</i> inhibitory effects of vemurafenib and sunitinib on kinase activity status.</p><p>Results</p><p>Overall kinase activity was significantly higher in lysates from melanoma tumors compared to normal skin tissue. Furthermore, <i>ex-vivo</i> incubation with both vemurafenib and sunitinib caused significant decrease in phosphorylation of kinase substrates, i.e kinase activity. While basal phosphorylation profiles were similar in <i>BRAF</i> wild-type and <i>BRAF</i>(V600E) tumors, analysis with <i>ex-vivo</i> vemurafenib treatment identified a subset of 40 kinase substrates showing stronger inhibition in <i>BRAF</i>(V600E) tumor lysates, distinguishing the <i>BRAF</i> wild-type and <i>BRAF</i>(V600E) tumors. Interestingly, a few <i>BRAF</i> wild-type tumors showed inhibition profiles similar to <i>BRAF</i>(V600E) tumors. The kinase inhibitory effect of vemurafenib was subsequently analyzed in cell lines harboring different <i>BRAF</i> mutational status with various vemurafenib sensitivity <i>in-vitro</i>.</p><p>Conclusions</p><p>Our findings suggest that multiplex kinase substrate array analysis give valuable information about overall tumor kinase activity. Furthermore, intra-assay exposure to kinase inhibiting drugs may provide a useful tool to study mechanisms of resistance, as well as to identify predictive markers.</p></div